BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19449011)

  • 1. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept.
    Halbig M; Horneff G
    Rheumatol Int; 2009 Dec; 30(2):229-38. PubMed ID: 19449011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis.
    Prince FH; Geerdink LM; Borsboom GJ; Twilt M; van Rossum MA; Hoppenreijs EP; Cate RT; Koopman-Keemink Y; van Santen-Hoeufft M; Raat H; van Suijlekom-Smit LW
    Ann Rheum Dis; 2010 Jan; 69(1):138-42. PubMed ID: 19581280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
    Klotsche J; Minden K; Thon A; Ganser G; Urban A; Horneff G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.
    Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Singer NG; Chon Y; Lin SL; Baumgartner SW;
    Arthritis Rheum; 2009 Sep; 60(9):2794-804. PubMed ID: 19714630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis.
    Geikowski T; Becker I; Horneff G;
    Rheumatology (Oxford); 2014 Jul; 53(7):1245-9. PubMed ID: 24599916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Hyrich KL; Davies R; Lunt M; Southwood TR;
    Rheumatology (Oxford); 2015 Jul; 54(7):1279-85. PubMed ID: 25638806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study.
    Schmeling H; Mathony K; John V; Keysser G; Burdach S; Horneff G
    Ann Rheum Dis; 2001 Apr; 60(4):410-2. PubMed ID: 11247875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis.
    Wallace CA; Ringold S; Bohnsack J; Spalding SJ; Brunner HI; Milojevic D; Schanberg LE; Higgins GC; O'Neil KM; Gottlieb BS; Hsu J; Punaro MG; Kimura Y; Hendrickson A
    J Rheumatol; 2014 Dec; 41(12):2459-65. PubMed ID: 25179849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.
    Pratsidou-Gertsi P; Trachana M; Pardalos G; Kanakoudi-Tsakalidou F
    Clin Exp Rheumatol; 2010; 28(6):919-22. PubMed ID: 21205467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
    Nerome Y; Imanaka H; Nonaka Y; Takei S
    Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Davies R; Southwood TR; Kearsley-Fleet L; Lunt M; Hyrich KL;
    Arthritis Rheumatol; 2015 Sep; 67(9):2487-94. PubMed ID: 25989609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.
    Windschall D; Müller T; Becker I; Horneff G
    Clin Rheumatol; 2015 Jan; 34(1):61-9. PubMed ID: 25034081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.
    Katsicas MM; Russo RA
    Clin Exp Rheumatol; 2005; 23(4):545-8. PubMed ID: 16095128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
    Yeh KW; Lee CM; Chang CJ; Lin YJ; Huang JL
    PLoS One; 2014; 9(6):e90757. PubMed ID: 24603504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis.
    Lamot L; Bukovac LT; Vidovic M; Frleta M; Harjacek M
    Clin Exp Rheumatol; 2011; 29(1):131-9. PubMed ID: 21345300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
    Lahdenne P; Vähäsalo P; Honkanen V
    Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.